Market Intel: Innovation, Surgical Techniques Drive Arthroscopy, Sports Medicine Products Market

The global market for arthroscopy products and sports medicine devices is expected to reach $9bn by 2023, a CAGR of 4.2%, driven by technological advancements, improved surgical techniques and a growing number of surgeons performing minimally invasive surgeries. With hip fixation devices expected to see double-digit growth by 2023, we'll take a closer look at recent technological innovations driving this sector, the key players, and also offer viewpoints from four orthopedic surgeons on what is driving their decision to adopt technologies. We'll also highlight the latest arthroscopes on the market, which is the fastest-growing segment in the global arthroscopy products market.

Sports hip injury koncept - Illustration

Global sales for arthroscopy products and sports medicine devices are expected to reach $9bn by 2023, representing a CAGR of 4.2% from 2018. Over the last few years, the value of the sports medicine market has risen to be nearly equal to the arthroscopy market. Within the combined market, arthroscopy products accounted for 51.9% of sales and sports medicine implants account for the remaining 48.1%. By 2023, the smaller sports medicine sector is expected to surpass arthroscopy product sales. (Also see "Device Week, 10 May 2019 – Global Arthroscopy Products Market; Biotronik Starts First ICD Study Looking At Sex-Specific Outcomes " - Medtech Insight, 10 May, 2019.)

According to a new report by Informa's Meddevicetracker, "Arthroscopy Products and Sports Medicine Implants," worldwide sales of arthroscopy products...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Orthopedics

More from Device Area

  • Owkin Teams With AstraZeneca To Develop AI-Based Breast Cancer Prescreening Tool

     

    Biopharmaceutical giant AstraZeneca has partnered with start-up “unicorn” Owkin to develop an AI-powered tool to prescreen for gBRCA mutations on the basis of morphological features in digitized pathology slides. Built on extensive, high-quality data sourced from the France-based PortrAIt consortium, the AI will help to prioritize patients for further testing, streamlining the diagnostic process, Owkin says.

  • Route 92 To Drive FreeClimb Neurointervention Sales With Extended Series F Funding

     

    An additional $50m brings the neurovascular intervention specialist’s total Series F funding to $82m. Route 92 says it will use the capital to build its sales and support teams and pursue regulatory authorizations around the globe for its FreeClimb portfolio while advancing its SUMMIT MAX clinical trial for the investigational Monopoint Reperfusion System.

  • TRiCares Initiates EU Pivotal Study For Topaz Tricuspid Valve Replacement

     

    TRiCares announced first implantation of the Topaz transfemoral tricuspid heart valve replacement system as part of the company’s EU pivotal study. If all goes to plan, the device will compete with Edwards’ Evoque system. The announcement follows the company’s $50m series D funding raise in July.